Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Induced Pluripotent Stem Cell Meets Severe Combined Immunodeficiency Publisher



Kouchaki R1 ; Abdnikfarjam B2 ; Maali A3 ; Abroun S4 ; Foroughi F2 ; Ghaffari S5 ; Azad M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
  2. 2. Department of Immunology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
  3. 3. Student Research Committee, Pasteur Institute of Iran, Tehran, Iran
  4. 4. Department of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  5. 5. Hematology Department, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Cell Journal Published:2020


Abstract

Severe combined immunodeficiency (SCID) is classified as a primary immunodeficiency, which is characterized by impaired T-lymphocytes differentiation. IL2RG, IL7Ralpha, JAK3, ADA, RAG1/RAG2, and DCLE1C (Artemis) are the most defective genes in SCID. The most recent SCID therapies are based on gene therapy (GT) of hematopoietic stem cells (HSC), which are faced with many challenges. The new studies in the field of stem cells have made great progress in overcoming the challenges ahead. In 2006, Yamanaka et al. achieved reprogramming technology by introducing four transcription factors known as Yamanaka factors, which generate induced pluripotent stem cells (iPSC) from somatic cells. It is possible to apply iPSC-derived HSC for transplantation in patients with abnormality or loss of function in specific cells or damaged tissue, such as T-cells and NK-cells in the context of SCID. The iPSC-based HSC transplantation in SCID and other hereditary disorders needs gene correction before transplantation. Furthermore, iPSC technology has been introduced as a promising tool in cellular-molecular disease modeling and drug discovery. In this article, we review iPSC-based GT and modeling for SCID disease and novel approaches of iPSC application in SCID. © 2020 Royan Institute (ACECR). All rights reserved.
Related Docs
View other Related Docs
1. A Review on Leukemia and Ipsc Technology: Application in Novel Treatment and Future, Current Stem Cell Research and Therapy (2018)
2. The Gene Expression Profile and Dna Methylation Pattern of Cdh1 and Dnmt1 Genes in Acute Promyelocytic Leukemia (Apl), Reports of Biochemistry and Molecular Biology (2020)
3. Promoter Methylation Status and Expression Levels of Rassf1a Gene in Different Phases of Acute Lymphoblastic Leukemia (All), International Journal of Hematology-Oncology and Stem Cell Research (2021)
4. Peaceful Existence of Tumor Cells With Their Non-Malignant Neighbors: The Trade of Tumor Cells With Tumor Micro-Environment, Current Chemical Biology (2020)
5. Generation of Ccr5-Ablated Human Induced Pluripotent Stem Cells As a Therapeutic Approach for Immune-Mediated Diseases, Iranian Journal of Allergy# Asthma and Immunology (2019)
6. Toward in Vitro Production of Platelet From Induced Pluripotent Stem Cells, Stem Cell Reviews and Reports (2022)
7. Human Dna-Dependent Protein Kinase Catalytic Subunit Deficiency: A Comprehensive Review and Update, Journal of Allergy and Clinical Immunology (2024)
8. Genetic Mutations and Immunological Features of Severe Combined Immunodeficiency Patients in Iran, Immunology Letters (2019)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (5)
Nima Parvaneh (3)
Other Related Docs
9. Dyskeratosis Congenita Future: Hematopoietic Stem Cell Transplantation or Gene Therapy?, Gene Reports (2025)
10. Immunodeficiencies, Clinical Immunology (2022)
11. Recent Advances in Gene Therapy and Modeling of Chronic Granulomatous Disease, Iranian Journal of Allergy# Asthma and Immunology (2019)
12. Eosinophils in the Tumor Microenvironment: Implications for Cancer Immunotherapy, Journal of Translational Medicine (2023)
13. Whole-Heart Tissue Engineering and Cardiac Patches: Challenges and Promises, Bioengineering (2023)
14. Cell-Based Vaccines: Frontiers in Medical Technology for Cancer Treatment, Regenerative Engineering and Translational Medicine (2024)
15. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
16. Clinical, Immunological and Molecular Findings of 8 Patients With Typical and Atypical Severe Combined Immunodeficiency: Identification of 7 Novel Mutations by Whole Exome Sequencing, Genes and Immunity (2023)
17. Crispr/Cas System: A Powerful Strategy to Improve Monogenic Human Diseases As Therapeutic Delivery; Current Applications and Challenges, Current Gene Therapy (2025)
18. A Novel Non-Frameshift Ada Deletion Detected by Whole Exome Sequencing in an Iranian Family With Severe Combined Immunodeficiency, Iranian Journal of Allergy# Asthma and Immunology (2020)
19. A Novel Homozygous Rag1 Mutation Is Associated With Severe Combined Immunodeficiency and Neurological Presentations, Allergologia et Immunopathologia (2021)
20. Demographic, Clinical, Immunological, and Molecular Features of Iranian National Cohort of Patients With Defect in Dclre1c Gene, Allergy# Asthma and Clinical Immunology (2023)